FRNM

Freenome, Inc. - Common stock (FRNM)

About Freenome, Inc. - Common stock (FRNM)

Freenome, Inc. operates as an early detection company, which engages in the development of blood-based screening tests to detect cancer. Its proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. The company was founded by Riley Ennis in 2014 and is headquartered in Brisbane, CA.

Details

Daily high

$16.35

Daily low

$15.48

Price at open

$15.75

52 Week High

$17.50

52 Week Low

$9.95

Market cap

1.8B

Dividend yield

Volume

813,565

Avg. volume

866,088

P/E ratio

-234.15

Freenome, Inc. - Common stock News